Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia

The article addresses the use of cefazolin in treating bacteremia caused by methicillin-susceptible Staphylococcus aureus (MSSA). Cefazolin is a first-generation cephalosporin traditionally used to treat infections caused by susceptible bacteria. Methicillin-susceptible Staphylococcus aureus is a type of bacteria that is susceptible to certain antibiotics including methicillin and its analogs. The study was published in the New England Journal of Medicine in June 2026. The article presents clinical findings on the efficacy and safety of cefazolin as a treatment option for patients with this specific infection. The research contributes to understanding optimal antibiotic strategies in treating MSSA bacteremia.